Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7431.092 | 1.0146 | 1.0195 | 1.5006 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7431.092 | 0.9548 | 0.9392 | 1.5006 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7431.092 | 0.7435 | 0.6415 | 1.5006 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7431.092 | 0.5871 | 0.4025 | 1.5006 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7431.092 | 0.0105 | -0.9038 | 1.5006 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7431.092 | 0.0034 | -0.9544 | 1.5006 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7432.091 | 0.9719 | 0.9450 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7432.091 | 1.0095 | 1.0186 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7432.091 | 0.9977 | 0.9955 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7432.091 | 0.9445 | 0.8913 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7432.091 | 0.9297 | 0.8624 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7432.091 | 0.9037 | 0.8115 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7432.091 | 0.8054 | 0.6185 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7432.091 | 0.0131 | -0.9712 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7432.091 | 0.0017 | -0.9960 | 1.0227 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7433.09 | 1.0769 | 1.1827 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7433.09 | 1.1166 | 1.2779 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7433.09 | 1.0295 | 1.0697 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7433.09 | 1.0773 | 1.1836 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7433.09 | 1.1256 | 1.2996 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7433.09 | 0.9552 | 0.8947 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7433.09 | 0.8328 | 0.6117 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7433.09 | 0.0124 | -0.9888 | 0.8477 | |
| HCC1187 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7433.09 | 0.0098 | -0.9914 | 0.8477 | |
| HCC1395 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7435.091 | 0.9771 | 0.9206 | 0.5716 |